Retrospective Study
Copyright ©The Author(s) 2016.
World J Gastroenterol. Apr 21, 2016; 22(15): 4034-4040
Published online Apr 21, 2016. doi: 10.3748/wjg.v22.i15.4034
Table 1 Patients’ demographics and clinical characteristics by group n (%)
VariablesSR + sorafenibSRP value
(n = 12)(n = 24)
Age1, yr49.8 ± 6.552.8 ± 6.90.226
ECOG PS score21.000
010 (83.3)19 (79.2)
12 (16.7)5 (20.8)
Largest tumor diameters1, cm9.8 ± 2.111.2 ± 2.50.103
Pathologic results30.404
Well differentiated (grade 1)3 (25.0)2 (8.3)
Moderately differentiated (grade 2)7 (58.3)18 (75)
Poorly differentiated (grade 3)2 (16.7)4 (16.7)
Satellite lesion4, n4 (33.3)9 (37.5)1.000
AFP0.700
< 400 ng/mL4 (33.3)6 (25)
≥ 400 ng/mL8 (66.7)18 (75)
HBV-DNA0.664
< 1000 cps/mL9 (75)20 (83.3)
≥ 1000 cps/mL3 (25)4 (16.7)
Degree of fibrosis51.000
0-22 (16.7)3 (12.5)
3-410 (83.3)21 (87.5)
Types of PVTT60.764
First-order branch (VP3)10 (83.3)19 (79.2)
Main trunk (VP4)2 (16.7)5 (20.8)
Preoperative laboratory results
ALT1, μmol/L57.3 ± 19.950.8 ± 22.10.397
Albumin1, g/L39.5 ± 3.539.9 ± 4.50.781
Bilirubin1, μmol/L17.4 ± 4.519.8 ± 6.00.236
Hemoglobin1, g/L137.3 ± 10.9132.0 ± 7.80.103
Platelet count1, 109/L185.4 ± 46.2164.3 ± 48.60.220
Prothrombin time1, s12.1 ± 1.012.0 ± 1.00.785
INR71.4 ± 0.51.3 ± 0.40.436
Blood loss7, mL304.2 ± 151.4343.8 ± 143.20.458
Blood transfusion7, mL37.5 ± 93.262.5 ± 124.50.679
Surgery time7, min218.3 ± 33.3232.5 ± 47.80.265
TTP times8, mo26.5 (14-54)21.5 (9-34)0.0419
Patients with recurrence after SR26 (50)18 (75)0.157
Survival times8, mo32 (21-58)25.5 (11-37)0.0109
Patients died after SR25 (41.7)14 (58.3)0.483